Zealand Pharma — Juni 2023
-
“With our long heritage in researching and developing new treatments for cardiovascular, renal, and metabolic conditions, we are extremely encouraged by these robust and compelling Phase II data,” said Carinne Brouillon, Head of Human Pharma, Boehringer Ingelheim. “Survodutide may become the first anti-obesity medication to reduce appetite while increasing energy expenditure through the liver. We look forward to furthering our discussions with health authorities to advance this dual receptor ago
-
Jeg glemt vist nok at sige god morgen tidligere men så tager vi lige den nu - God morgen på endnu en flot solskins dag!
-
Zealand Pharma: Data shows nearly 19% weight loss https://www.proinvestor.com/boards/113406
-
SMADK - Det var aboslut interessante citater fra Carinne Brouillon.
-
-
AstraZeneca har droppe udviklingen af AZD0186, som var en oral GLP-1. Det er anden GLP-1 kandidat, som AZ har droppe og de lukker nu GLP-1 programmet ned. https://www.fiercebiotech.com/biotech/astrazeneca-drops-another-glp-1-after-phase-1-data-busts-market-beating-diabetes-hopes
-
Her er en artikel, hvor læge og Boehringer Ingelheim’s corporate vice president og chef for cardiometabolisk medicin, Waheed Jamal, udtaler sig om den læringskurve som BI har været igennem i tolkningen af studiet. https://www.fiercebiotech.com/biotech/boehringers-phase-2-obesity-prospect-sees-19-weight-loss-high-dose-patients
-
“What we'll take forward into the phase 3 is that we will have a much lower titration—probably somewhere around every four weeks as opposed to every two weeks that we've had in phase 2,” he said. “We will allow plenty of flexible titration throughout the trial in phase 3.”
Boehringer is now in discussions with regulators about launching a phase 3 trial, Jamal said, though he didn’t reveal an anticipated timeline. https://www.fiercebiotech.com/biotech/boehringers-phase-2-obesity-prospect-sees-
-
Tak ApS invest. Dette link duer. https://www.fiercebiotech.com/biotech/boehringers-phase-2-obesity-prospect-sees-19-weight-loss-high-dose-patients
-
Lægger alle de relevant links ind her de kommende dage: https://www.proinvestor.com/boards/113406/
-
Medwatch:
"Zealand Pharma og den tyske partner Boehringer Ingelheim har serveret yderligere data fra et fase 2-studie med fedmekandidaten Survodutid BI 456906.
De peger på endnu mere udtalte vægttab, når man bliver på behandlingen i længere tid, og de viser også, at Zealand og Boehringer Ingelheim ikke har set udviklingen stoppe efter de 46 uger, som studiet løb".
Zealand Pharma og partner serverer flere data fra lovende fedmekandidat
De peger bl.a. på endnu mere udtalte vægttab, når man bliver på behandlingen i længere tid.
(medwatch.dk)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind